Investigational drug · Phase 3
linsitinib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
27
Any phase or sponsor naming "linsitinib"
First trial start
2023
Oct 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "linsitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Graves Orbitopathy
- Thyroid Eye Disease, TED
- Thyroid Eye Disease
- Endocrine System Diseases
- Eye Diseases
- Thyroid Associated Ophthalmopathy
- Graves Ophthalmopathy
- Thyroid Diseases
- Orbital Diseases
- Proptosis
Approved drugs for the same conditions: Endocrinology and women's health · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "linsitinib" as an intervention, largest first.
- Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01186861 · 205 participants · Start Mar 4, 2011 · Primary completion Jul 1, 2013
Drug: OSI-906; erlotinib and 1 more · For: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Sites: Jacksonville, Florida; Port Saint Lucie, Florida; Albany, Georgia · 69 sites in all
- A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00889382 · 152 participants · Start Aug 5, 2009 · Primary completion Aug 1, 2014
Drug: OSI-906; Paclitaxel · For: Ovarian Cancer; Solid Tumors
Sites: Scottsdale, Arizona; Orange, California; Lafayette, Indiana · 46 sites in all
- A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00924989 · 139 participants · Start Dec 1, 2009 · Primary completion Jul 11, 2012
Drug: OSI-906 · For: Adrenocortical Carcinoma
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 35 sites in all
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)Pivotal-lookingRecruiting
Sling Therapeutics, Inc.Industry
NCT07753603 · 130 participants (planned) · Start Aug 4, 2026 · Primary completion Jun 30, 2028
Drug: linsitinib; Placebo · For: Thyroid Eye Disease, TED; Graves Orbitopathy
Sites: Glendale, Arizona; Beverly Hills, California; Canoga Park, California · 18 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT00739453 · 95 participants · Start Oct 23, 2008 · Primary completion Mar 3, 2012
Drug: OSI-906; erlotinib · For: Advanced Solid Tumors
Sites: Aurora, Colorado; Baltimore, Maryland; Detroit, Michigan · 4 sites in all
- Study of Continuous OSI-906 DosingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00514007 · 95 participants · Start Jun 18, 2007 · Primary completion Mar 19, 2012
Drug: OSI-906 · For: Advanced Solid Tumors
Sites: Nashville, Tennessee; Glasgow, United Kingdom
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Pivotal-lookingCompleted
Sling Therapeutics, Inc.Industry
NCT05276063 · 90 participants · Start Jul 1, 2022 · Primary completion Oct 15, 2024
Drug: Linsitinib; Placebo · For: Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases and 9 more
Sites: Beverly Hills, California; La Jolla, California; Los Angeles, California · 30 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT01221077 · 88 participants · Start Apr 8, 2011 · Primary completion Mar 1, 2013
Drug: OSI-906; Erlotinib and 1 more · For: NSCLC; Non Small Cell Lung Cancer
Sites: La Jolla, California; Tampa, Florida; Weston, Florida · 29 sites in all
- Study of Intermittent OSI-906 DosingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00514306 · 79 participants · Start Jul 5, 2007 · Primary completion Sep 20, 2010
Drug: OSI-906 · For: Advanced Solid Tumors
Sites: Houston, Texas; Sutton, United Kingdom
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Pivotal-lookingRecruiting
Sling Therapeutics, Inc.Industry
NCT06112340 · 75 participants (planned) · Start Oct 11, 2023 · Primary completion Jun 2026
Drug: linsitinib · For: Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases and 9 more
Sites: Miami, Florida; Morgantown, West Virginia
Newest research
PubMed records naming it or its code names, newest first.
- Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma.
Kumar S, Kim YS, Sun NY, et al. · Cancer Res Commun 2026
- The dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation.
Luffy M, Wagner S, Wolf J, et al. · Front Immunol 2026
- Linsitinib: a tyrosine kinase inhibitor with dual host-parasite targeting potential against leishmaniasis.
Nharwal L, Beg MA, Singh R, et al. · Folia Microbiol (Praha) 2026
- Identification of MMP14 and FOS as key regulators of vascular smooth muscle cell senescence in diabetic kidney disease: A combined bioinformatics and experimental study.
Qu B, He Y, Wang B, et al. · Arch Gerontol Geriatr 2026
- Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Asmar C, Asmar R, Awad G, et al. · Clin Transl Oncol 2026
- A primary hepatopancreatic cell platform enables cellular dissection of glucose metabolism and endocrine-metabolic regulation in Litopenaeus vannamei.
Song X, Liu Z, Liu J, et al. · Front Endocrinol (Lausanne) 2026
Also in development for Graves Orbitopathy
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.